Integra LifeSciences Holdings Corporation (IART) Analysts See $0.56 EPS

February 16, 2018 - By Nellie Frank

 Integra LifeSciences Holdings Corporation (IART) Analysts See $0.56 EPS
Investors sentiment increased to 1.29 in Q3 2017. Its up 0.15, from 1.14 in 2017Q2. It increased, as 22 investors sold Integra LifeSciences Holdings Corporation shares while 60 reduced holdings. 26 funds opened positions while 80 raised stakes. 68.21 million shares or 2.93% more from 66.26 million shares in 2017Q2 were reported.
California-based Schwab Charles Mngmt Inc has invested 0.01% in Integra LifeSciences Holdings Corporation (NASDAQ:IART). Proshare Advisors Lc reported 0% stake. Ameriprise Fincl invested 0.01% in Integra LifeSciences Holdings Corporation (NASDAQ:IART). Stevens Cap Management L P has invested 0.02% in Integra LifeSciences Holdings Corporation (NASDAQ:IART). Aqr Cap Mngmt Ltd reported 17,644 shares or 0% of all its holdings. Sector Gamma As reported 4.07% in Integra LifeSciences Holdings Corporation (NASDAQ:IART). Bnp Paribas Arbitrage Sa reported 0% of its portfolio in Integra LifeSciences Holdings Corporation (NASDAQ:IART). Fdx Advisors stated it has 0.01% of its portfolio in Integra LifeSciences Holdings Corporation (NASDAQ:IART). Parkside Bancshares has 353 shares. Hood River Cap Mgmt Limited Liability owns 293,179 shares for 0.94% of their portfolio. Tower Cap Ltd Liability Corp (Trc) invested in 0.03% or 6,538 shares. Vaughan Nelson Invest Management L P holds 895,975 shares or 0.54% of its portfolio. Price T Rowe Md has 0% invested in Integra LifeSciences Holdings Corporation (NASDAQ:IART). Ngam Advsr Limited Partnership has 0.04% invested in Integra LifeSciences Holdings Corporation (NASDAQ:IART). Voya Invest Mngmt Limited Liability Co invested in 0% or 28,469 shares.

Analysts expect Integra LifeSciences Holdings Corporation (NASDAQ:IART) to report $0.56 EPS on February, 22.They anticipate $0.04 EPS change or 7.69 % from last quarter’s $0.52 EPS. IART’s profit would be $43.94M giving it 23.25 P/E if the $0.56 EPS is correct. After having $0.45 EPS previously, Integra LifeSciences Holdings Corporation’s analysts see 24.44 % EPS growth. The stock increased 1.24% or $0.64 during the last trading session, reaching $52.07. About 37,614 shares traded. Integra LifeSciences Holdings Corporation (NASDAQ:IART) has risen 32.67% since February 16, 2017 and is uptrending. It has outperformed by 15.97% the S&P500.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) Ratings Coverage

Among 15 analysts covering Integra Lifesciences Holdings Corp. (NASDAQ:IART), 8 have Buy rating, 0 Sell and 7 Hold. Therefore 53% are positive. Integra Lifesciences Holdings Corp. had 35 analyst reports since July 29, 2015 according to SRatingsIntel. On Wednesday, June 7 the stock rating was maintained by UBS with “Buy”. JMP Securities upgraded the stock to “Mkt Outperform” rating in Friday, January 6 report. Oppenheimer maintained Integra LifeSciences Holdings Corporation (NASDAQ:IART) on Wednesday, July 26 with “Buy” rating. The stock of Integra LifeSciences Holdings Corporation (NASDAQ:IART) earned “Buy” rating by Jefferies on Tuesday, May 30. The firm has “Neutral” rating given on Friday, October 27 by JP Morgan. Lake Street maintained the shares of IART in report on Thursday, April 28 with “Hold” rating. The stock of Integra LifeSciences Holdings Corporation (NASDAQ:IART) has “Overweight” rating given on Monday, August 3 by JP Morgan. The rating was maintained by Jefferies on Tuesday, October 10 with “Buy”. As per Friday, October 28, the company rating was upgraded by Lake Street. J.P. Morgan downgraded Integra LifeSciences Holdings Corporation (NASDAQ:IART) on Friday, October 27 to “Hold” rating.

Integra LifeSciences Holdings Corporation develops, makes, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company has market cap of $4.09 billion. The firm operates through two divisions, Specialty Surgical Solutions; and Orthopedics and Tissue Technologies. It has a 85.22 P/E ratio. It offers neurosurgery and critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment.

More notable recent Integra LifeSciences Holdings Corporation (NASDAQ:IART) news were published by: Seekingalpha.com which released: “Integra LifeSciences Holdings’ (IART) CEO Peter Arduini on Q3 2017 Results …” on October 26, 2017, also Globenewswire.com with their article: “Integra LifeSciences Completes the Acquisition of Codman Neurosurgery Business …” published on October 02, 2017, Zacks.com published: “Integra LifeSciences Global Prospects Solid, Competition Rife” on February 02, 2018. More interesting news about Integra LifeSciences Holdings Corporation (NASDAQ:IART) were released by: Seekingalpha.com and their article: “Integra LifeSciences Holdings (IART) Q2 2017 Results – Earnings Call Transcript” published on July 26, 2017 as well as Globenewswire.com‘s news article titled: “Integra LifeSciences to Host Fourth Quarter 2017 Earnings Results Conference …” with publication date: February 01, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: